The Four Classes of Hep C Treatment DAAs

DAAsCurrent hepatitis C treatments are made up of combinations of drugs called direct-acting antivirals (DAAs). DAAs directly target the hep C virus in different ways to stop it from making copies of itself and do this so well that they promise a much brighter future for people living with hepatitis C. DAAs promise treatments with shorter treatment times, much higher cure rates, and fewer side effects.

There are four classes of direct-acting antivirals that combine in different ways to make up the different hep C DAA treatments.

The Four Classes of DAAs

The Four Classes of DAAs Very Roughly What the DAAs Do DAAs Not Covered by BC PharmaCare (Targeted Genotypes in brackets) DAAs Covered by BC PharmaCare (Targeted Genotypes in brackets)
NS3/4A Protease Inhibitors (PIs) NS3/4A protease inhibitors work by blocking a viral enzyme (protease) that enables the hep C virus to survive and replicate in host cells.
Nucleoside and Nucleotide NS5B Polymerase Inhibitors They directly target the hep C virus to stop it from making copies of itself in the liver. They attach themselves onto the genetic information, called RNA, to block the virus from multiplying.
NS5A Inhibitors They block a virus protein, NS5A, that HCV needs to reproduce and for various stages of infection.
Non-Nucleoside NS5B Polymerase Inhibitors They work to stop HCV from reproducing by inserting themselves into the virus so that other pieces of the hep C virus cannot attach to it.
*AbbVie’s Holkira Pak is a treatment made up of 3 DAAs (ombitasvir, paritaprevir, and dasabuvir) and ritonavir. Ritonavir is a booster for paritaprevir, a protease inhibitor (PI). Holkira Pak treats hep C genotype 1a/b. Technivie is a treatment made up of 2 DAAs (ombitasvir and paritaprevir) and ritonavir. It treats hep C genotype 4 infections.
**BC PharmaCare covers Sovaldi to treat hep C genotypes 1-3 but doesn’t cover it to treat genotypes 4-6.
***Sofosbuvir and ledipasvir make up Harvoni and sofosbuvir and velpatasvir make up Epclusa.